医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Yamaha Motor Ventures & Laboratory Silicon Valley Leads Seed Funding Round for Australian Health Technology Startup loop+

2020年01月28日 AM05:03
このエントリーをはてなブックマークに追加


 

PALO ALTO, Calif.

Yamaha Motor Ventures & Laboratory Silicon Valley (“YMVSV”), the strategic business development and investment arm of Yamaha Motor Co., Ltd. (“YMC”) (Tokyo: 7272), today announced it led an AUD $3 million seed funding round for loop+, an early stage health technology enterprise based in Australia developing a pressure and movement tracking device for wheelchair-bound patients. Leveraging the USD $100 million Yamaha Motor Exploratory Fund (the “Fund”), the loop+ investment reflects YMVSV’s growing interest in teams working to develop technological solutions to major healthcare challenges.

“Yamaha Motor is actively supporting innovation in the health tech sector to help bring technology to the market to address challenges and leverage opportunities for better patient care. loop+ is one such company, taking a preventative health approach to help avoid suffering and lower costs associated with prevalent pressure-related conditions for wheelchair users,” said George Kellerman, CEO & Managing Director of YMVSV.

The oversubscribed seed funding round for loop+ led by YMVSV raised a total of AUD $3 million with additional investments from Giant Leap Fund, Eleanor Venture and other investors based in Australia.

“The active monitoring of wheelchair bound patients offers a variety of benefits to the patient, caregivers and, ultimately, the cost of that care,” said Rebecca Woodcock, Principal and Global Health Tech lead for YMVSV who joined the loop+ board of directors December 5, 2019. “We are looking forward to working with the loop+ team to explore the product’s potential and support its global market introduction.”

The loop+ platform features a wheelchair sensor mat that continuously measures pressure, position, environmental conditions like humidity, and general activity throughout the day. This alerts healthcare professionals to potential risks like pressure wounds allowing for early intervention and prevention as well as to promote healthy wheelchair habits and reduce the acceleration of scoliosis and respiratory issues.

“It is tremendously exciting to be working with Yamaha Motor Ventures to scale our enterprise and deliver the loop+ device to wheelchair users,” said Kath Hamilton, co-founder and CEO of loop+.

About loop+

loop+ is an early-stage digital therapeutic device manufacturer using sensor technology to continuously monitor patients with chronic conditions at home who are at high risk of health complications. The platform gives patients and their circle of care visibility into how their actions and daily behaviors contribute to their health outcomes. Based in New South Wales, Australia, loop+ helps people take charge of their health, helping them to build sustainable healthy habits.

For more information, visit www.loopplus.com.au.

About Yamaha Motor Ventures & Laboratory Silicon Valley

Yamaha Motor Ventures & Laboratory Silicon Valley is a wholly-owned subsidiary of YMC. Founded in 2015 in support of YMC’s long-term goal to contribute to society through business, YMVSV manages the Yamaha Motor Exploratory Fund, a USD $100 million investment fund with a 10-year lifecycle focused on seed to Series B investments. Headquartered in the home of innovation, Silicon Valley, Calif., YMVSV offers a wealth of business development resources to startup companies to drive innovation forward in the fields of mobility, sustainability, robotics, food and agriculture, health and wellness, and aviation.

For more information visit www.ymvsv.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005118/en/

CONTACT

MEDIA CONTACT:

Lisa Spicer

For Yamaha Motor Ventures & Laboratory Silicon Valley

Lisa.spicer@specpr.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高